Barrier Therapeutics (BTRX) Releases Positive Results in Phase 2 Study of Pramiconazole
Barrier Therapeutics (Nasdaq: BTRX) today announced promising results from an on-going Phase 2a study of pramiconazole, an oral based antifungal product candidate for patients with oncychomycosis (nail fungus) of the toenails.
Dr. Braham Shroot, Chief Scientific Officer of Barrier Therapeutics said, "These data further demonstrate pramiconazole's broad spectrum activity against dermatophytes, yeasts and molds, and, given the encouraging mycological and clinical efficacy in nail fungus, we believe the program warrants full development in this highly prevalent infection."
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the development and commercialization of pharmaceutical products in the field of dermatology. Barrier markets several prescription pharmaceutical products to the United States and Canada: Xolegel, Vusion, Solage, VANIQA and Denavir.
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
